Clinical trials: Hemodialysis
End Stage Renal Disease
Safety and Dose Finding Study of Xigris in Hemodialysis Patients
The purpose of the study is to assess the safety of Xigris (Drotrecogin alfa) as an anticoagulant at different dose levels during dialysis treatment in patients with End Stage Renal Disease (ESRD).
- Trial name
- Xigris1003 (NCT01227187)
- Testing
- Drotrecogin alfa activated (Xigris)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- George Washington University
Secondary Hyperparathyroidism, Hemodialysis
Paricalcitol Compared to Maxacalcitol in Chronic Kidney Disease Patients With Secondary Hyperparathyroidism
This study is a exploratory comparison of the efficacy and safety of paricalcitol injection with maxacalcitol injection in chronic kidney disease participants receiving hemodialysis with secondary hyperparathyroidism.
- Trial name
- NCT00990704
- Testing
- paricalcitol, maxacalcitol
- Where
- 14 sites in Japan
- Volunteers
- 47 people
- Sponsor
- Abbott
Secondary Hyperparathyroidism, Hemodialysis
Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism
This study is a comparison of the efficacy and safety of paricalcitol injection with maxacalcitol injection in adult Japanese chronic kidney disease patients receiving hemodialysis with secondary hyperparathyroidism.
- Trial name
- NCT01341782
- Testing
- paricalcitol, maxacalcitol
- Where
- 45 sites in Japan
- Volunteers
- 255 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Improve Endothelial Function and Decrease Vascular Stenosis
Phosphodiesterase Type 5 Inhibition to Improve Endothelial Function and Vascular Remodeling in Chronic Kidney Disease and End Stage Renal Disease Patients Requiring New Arteriovenous Fistula
Patients with stage IV and V chronic kidney disease and end stage renal disease requiring hemodialysis at University of Alabama at Birmingham (UAB) Dialysis Clinics will be recruited from the UAB Vascular Access Clinic, which has…
- Trial name
- NCT02414204
- Testing
- Sildenafil
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Alabama at Birmingham
Chronic Renal Failure, Chronic Kidney Disease
A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin
The purpose of this study is to demonstrate therapeutic equivalence of subcutaneous (SC) Epoetin Hospira compared to SC Epogen (Amgen), based on maintenance of hemoglobin (Hb) levels and study drug dose requirements in patients…
- Trial name
- AiME - 13 (NCT01473420)
- Testing
- Epoetin Hospira, Epogen Amgen
- Where
- 73 sites in United States
- Volunteers
- 320 people
- Sponsor
- Pfizer
COVID-19
Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis Patients
Thymalfasin (thymosin alpha 1 or Ta1), the active pharmaceutical ingredient in ZADAXIN® injection, is a 28-amino acid synthetic peptide, identical to natural Ta1 produced by the thymus gland.
- Trial name
- Ta1 (NCT04428008)
- Testing
- Thymalfasin
- Where
- United States
- Volunteers
- 189 people
- Sponsor
- William B. Ershler, MD
Dysfunctional Hemodialysis Catheters
A Study of Tenecteplase for Restoration of Function in Dysfunctional Hemodialysis (HD) Catheters
This was a Phase III, open-label study conducted at 44 centers in the United States, Canada, and Puerto Rico. 223 subjects who required hemodialysis (HD) and had a dysfunctional HD catheter were enrolled in the study.
- Trial name
- TROPICS 4 (NCT00396253)
- Testing
- Tenecteplase
- Volunteers
- 223 people
- Sponsor
- Genentech, Inc.
Renal Insufficiency, Chronic, Anemia
Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
The purpose of this study is to compare two different dosing methods of epoetin alfa and their effectiveness in maintaining hemoglobin levels between 10.0 to 11.0 g/dL in in patients with chronic kidney disease (CKD) receiving…
- Conditions
- Renal Insufficiency, Chronic, Anemia, Renal Dialysis, Erythrocyte Transfusion
- Trial name
- NCT02253654
- Testing
- Epoetin alfa
- Where
- 37 sites in United States, Puerto Rico
- Volunteers
- 216 people
- Sponsor
- Amgen
Renal Failure
Preemptive Treatment With Grazoprevir and Elbasvir for Donor HCV Positive to Recipient HCV Negative Kidney Transplant
Proof of concept, open-label single center study for the donation of HCV positive kidneys to HCV negative patients, with preemptive, interventional treatment to prevent HCV transmission upon transplantation.
- Trial name
- NCT02945150
- Testing
- elbasvir (50mg) / grazoprevir (100mg) (fixed dose combination)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Massachusetts General Hospital
End Stage Renal Disease
Triferic Pediatric Pharmacokinetic Protocol
The main purpose is to determine the pharmacokinetics (PK) of Triferic iron administered intravenously in pediatric patients with chronic kidney disease on chronic hemodialysis (CKD-5HD).
- Trial name
- NCT02595437
- Testing
- Triferic
- Where
- 9 sites in United States
- Volunteers
- 22 people
- Sponsor
- Rockwell Medical Technologies, Inc.
Intradialytic Hypertension
Mechanisms and Treatment of Intradialytic Hypertension
1. To determine in a cross sectional case-controlled cohort study of 50 hemodialysis patients if blood pressure elevations with hemodialysis are associated with decreased endothelial cell function (measured by brachial artery…
- Trial name
- MATCH (NCT00827775)
- Testing
- Carvedilol
- Where
- 3 sites in United States
- Volunteers
- 55 people
- Sponsor
- University of Texas Southwestern Medical Center
Uremic Pruritus
Phase 3 Study of Difelikefalin in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus
This a multicentre study that consists of a 12-week double-blind period, and an optional 14-week open-label extension period and a 1-week follow-up period.
- Trial name
- NCT05885737
- Testing
- Difelikefalin Injection
- Where
- 35 sites in China
- Volunteers
- 260 people
- Sponsor
- Vifor Fresenius Medical Care Renal Pharma
Anemia
MIRACLE Study: A Study of Once-Monthly Intravenous Mircera in Hemodialysis Participants With Chronic Renal Anemia
This single-arm study will assess the long-term maintenance of hemoglobin levels, safety, and tolerability of once-monthly intravenous administration of Mircera in hemodialysis participants with chronic renal anemia.
- Trial name
- NCT00545571
- Testing
- Methoxy polyethylene glycol-epoetin beta
- Where
- 27 sites in Austria, Switzerland
- Volunteers
- 120 people
- Sponsor
- Hoffmann-La Roche
End-Stage Renal Disease, Secondary Hyperparathyroidism
A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis
The objective is to evaluate the safety of paricalcitol capsules in pediatric subjects, ages 10 to 16 years old, with Stage 5 chronic kidney disease (kidney failure) receiving peritoneal dialysis or hemodialysis and being treated…
- Trial name
- NCT01382212
- Testing
- paricalcitol
- Volunteers
- 13 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Anemia
A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.
This is the first study in hemodialysis subjects with anemia to evaluate the pharmacokinetics, safety, efficacy, tolerability, and pharmacodynamics of sotatercept (ACE-011)
- Trial name
- NCT01146574
- Testing
- Sotatercept
- Where
- 24 sites in United States
- Volunteers
- 50 people
- Sponsor
- Celgene
Cardiovascular Disease
Feasibility Study of Omega-3 Fatty Acids in Dialysis Patients
Cardiovascular disease and mortality is the largest comorbidity within the dialysis population. Nearly 50% of hemodialysis patients will have congestive heart failure at initiation.
- Trial name
- NCT01002118
- Testing
- Omega-3 Acid Ethyl Esters
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Iowa
End Stage Renal Disease, Olfactory Disorders
Helping Olfaction and Nutrition On Renal Replacement
This clinical trial examines whether nasal theophylline administration can improve olfaction and nutrition in hemodialysis patients.
- Trial name
- HONORR (NCT02479451)
- Testing
- Theophylline
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Massachusetts General Hospital
Kidney Failure
Quantitative Mass Transfer of SFP-iron From Dialysate to Blood in CKD-HD Patients
The purpose of this study is to determine the quantity of iron derived from SFP that is transferred from the dialysate to patients during a single dialysis session.
- Trial name
- NCT01894906
- Testing
- Soluble Ferric Pyrophosphate
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Rockwell Medical Technologies, Inc.
Renal Dialysis
Study of Self-monitoring of Weight & Blood Pressure (Via patientMpower Platform) in Hemodialysis
Pilot-scale study to assess the effect of self-monitoring using the patientMpower electronic health journal (pMp app) [+digital weighing scales \& BP monitor] on outcomes in ambulatory haemodialysis patients.
- Trial name
- NCT03403491
- Testing
- patientMpower application
- Where
- Ireland
- Volunteers
- 43 people
- Sponsor
- patientMpower Ltd.
End-Stage Renal Disease, Meals
Pilot Study of Nutrition in Maintenance Hemodialysis Patients
This pilot study aims to produce preliminary data on the safety of providing high-protein meals to patients during dialysis, and effects of this intervention on nutritional status and quality of life outcomes.
- Conditions
- End-Stage Renal Disease, Meals, Hemodialysis
- Trial name
- NCT02917278
- Testing
- Meals
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Purdue University